Our guidance for net revenue from collaborations and royalties remains a range between $100 million and $175 million. And our guidance for combined non-GAAP R&D and SG&A expenses remains unchanged and is a range between $1.575 billion and $1.65 billion. Let me now turn from financials and discuss some key goals and upcoming milestones slated for early and mid-2023. We will, of course, be executing on global commercialization of our products ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO. From our TTR programs, we have a couple of upcoming data presentations. 18-month results from APOLLO-B will be presented at the ESC Heart Failure Meeting later this month and the HELIOS-A randomized treatment extension results looking at a biannual dose regimen for vutrisiran will be presented at ASNP also at the end of May.
We expect to report top-line results from the KARDIA-1 Phase 2 study of zilebesiran and also intend to complete enrollment in the KARDIA-2 Phase 2 study. With our partner programs, VIR expect additional results from Phase 2 combination trials of ALN-HBV02. Let me now turn it back to Christine to coordinate our Q&A session. Christine?
Christine Lindenboom: Thank you, Jeff. Operator. We’ll now open a call for questions. To those delve we would like to ask you to limit yourself to one question each. Then get back in the queue if you have additional questions.
Q – Ritu Baral: Good morning, guys. Thanks for taking the question. I know I’m only loud one, so I’m going try and stick to it as much as I can. The 18 month data that we’re – that’s coming up from APOLLO-B, can you talk a little bit more about what will be presented? Maybe how many patients are in continued follow up at 18 months? Will we have key secondary endpoint like the Kansas City and additional safety follow up as well? Thank you.
Operator: Thank you very much. Our next question comes from Tazeen Ahmad from BofA. Your line is open.
Operator: Thank you. Our next question comes from Ellie Merle from UBS. Your line is open.
Operator: Thank you for your question. Our next question comes from Salveen Richter with Goldman Sachs. Your line is open.
Operator: Thank you. Our next question comes from Paul Matteis from Stifel. Your line is open.
Operator: Thank you for your question. Our next question, excuse me, comes from Jessica Fye from JPMorgan. Jessica, your line is open.
Operator: Thank you. Our next question comes from Gena Wang with Barclays. Your line is open.
Operator: Thank you. Our next question comes from David Lebowitz with Citi. Your line is open.
Operator: Thank you. Our next question is from Mike Ulz from Morgan Stanley. Your line is open.
Operator: Yes. Our final question of the day comes from Kostas Biliouris from BMO Capital Markets. Your line is open.
Yvonne Greenstreet: Great. So look, thanks for the question. And thanks to everyone for joining this call. We’re really happy with the strong start that we’ve made in 2023. We’ve got strong commercial execution, significant pipeline and platform development. We’d really underscore the power of RNAi Therapeutics and addressing major unmet needs for patients. And we look forward to sharing more progress with you in the coming months as we continue to deliver on both our near- and long-term goals. Thank you, everybody.
Christine Lindenboom: Goodbye.
Operator: Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.
